Utah VA Medical Center
Welcome,         Profile    Billing    Logout  
 8 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stehlik, Josef
NCT05420012: The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation

Completed
4
26
US
Vericiguat, VERQUVO, Placebo, Control group
Josef Stehlik, Merck Sharp & Dohme LLC
Heart Failure, Heart Failure with Reduced Ejection Fraction (HFrEF)
10/24
10/24
NCT03644667: Tocilizumab in Cardiac Transplantation

Active, not recruiting
2
385
US
tocilizumab, Actemra®, Placebo, Placebo for tocilizumab, Placebo for Actemra®, Standard of Care Triple IS, calcineurin inhibitor: (tacrolimus (Prograf ®)), anti-proliferative treatment: (mycophenolate mofetil ),, MMF, CellCept®, Myfortic®, enteric-coated mycophenolate sodium, steroids: methylprednisolone/prednisone
National Institute of Allergy and Infectious Diseases (NIAID), PPD
Heart Transplant
04/25
04/25
DETECT, NCT05081739: Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation

Withdrawn
N/A
600
NA
Prospera Transplant Assessment, Endomyocardial biopsy
Natera, Inc.
Heart Transplant Failure and Rejection
01/25
01/26
ACES-EMB, NCT06414603: A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

Recruiting
N/A
250
US
The Prospera™ Test
Natera, Inc.
Heart Transplant Failure and Rejection
12/24
12/25
NCT04707872: Trifecta-Heart cfDNA-MMDx Study

Recruiting
N/A
300
Europe, Canada, US, RoW
MMDx diagnostic test, Prospera, HLA antibody
University of Alberta, Natera, Inc., One Lambda
Heart Transplant Rejection
12/26
07/27
DEFINE-HT, NCT05309382: Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation

Completed
N/A
147
US
Prospera
Natera, Inc.
Heart Transplant
10/24
10/24

Download Options